0001733294false00017332942024-01-312024-01-31

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 31, 2024

Generation Bio Co.

(Exact Name of Registrant as Specified in Charter)

​

Delaware

    

001-39319

    

81-4301284

(State or Other Jurisdiction

of Incorporation)

​

(Commission

File Number)

​

(IRS Employer

Identification No.)

​

​

301 Binney Street

Cambridge, MA

    

02142 

(Address of Principal Executive Offices)

​

(Zip Code)

​

Registrant’s telephone number, including area code: (617) 655-7500

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

​

​

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

​

GBIO

​

Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

​

​

Item 1.02 Termination of a Material Definitive Agreement.

As previously reported, on July 13, 2021, Generation Bio Co. (the “Company”) entered into a lease agreement (the “Lease”) with Zinc II PropCo 2020, LLC, a Delaware limited liability company (together with its successors, agents and assigns, the “Landlord”), pursuant to which the Company leased approximately 104,000 square feet of a manufacturing facility located at 41 Seyon Street, Waltham, Massachusetts 02453 (the “Facility”). The material terms of the Lease were included in Item 1.01 of the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on July 14, 2021, which is incorporated by reference herein. The description of the Lease incorporated by reference is not complete and is subject to and qualified in its entirety by the Lease, a copy of which was filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, filed with the Commission on November 10, 2021.

On January 31, 2024, the Company notified the Landlord of the termination of the Lease due to the Landlord’s breach of its obligations to the Company under the Lease and returned possession of the premises to the Landlord. The Landlord has informed the Company that it disputes the Company’s claims of breach of the Lease and the Company’s right to terminate the Lease (even if it were in breach) and reserves all rights and remedies under the Lease and state law. In the event of any further action by the Landlord, the Company intends to defend its right to terminate the Lease.

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

GENERATION BIO CO.

Date: February 2, 2024

By:

/s/ Matthew Norkunas

Name: Matthew Norkunas, M.D., M.B.A.

Title: Chief Financial Officer

​

​

​

​

v3.24.0.1
Cover Page
Jan. 31, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jan. 31, 2024
Entity Registrant Name Generation Bio Co.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39319
Entity Tax Identification Number 81-4301284
Entity Address, Address Line One 301 Binney Street
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code 617
Local Phone Number 655-7500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Entity Central Index Key 0001733294
Amendment Flag false
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Generation Bio Charts.
Generation Bio (NASDAQ:GBIO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Generation Bio Charts.